2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 0 | 25.058 | 28.051 | 153.776 | 231.388 | 359.140 | 332.494 | 479.294 | 585.403 | 674.904 |
Total Income - EUR | 0 | 25.058 | 28.051 | 153.789 | 231.548 | 359.217 | 332.585 | 479.327 | 585.403 | 674.904 |
Total Expenses - EUR | 1.253 | 37.119 | 45.409 | 140.887 | 209.621 | 304.024 | 300.216 | 404.633 | 514.957 | 583.066 |
Gross Profit/Loss - EUR | -1.253 | -12.061 | -17.358 | 12.902 | 21.927 | 55.193 | 32.369 | 74.694 | 70.447 | 91.837 |
Net Profit/Loss - EUR | -1.253 | -12.827 | -17.639 | 11.364 | 19.611 | 51.588 | 29.295 | 70.474 | 64.707 | 79.162 |
Employees | 1 | 2 | 2 | 1 | 3 | 4 | 3 | 3 | 4 | 5 |
Check the financial reports for the company - Solius Pharm Srl
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 0 | 831 | 31 | 0 | 40 | 5.573 | 3.800 | 2.085 | 28.298 | 20.521 |
Current Assets | 360 | 21.784 | 33.083 | 64.253 | 82.751 | 96.771 | 119.445 | 192.261 | 214.228 | 354.489 |
Inventories | 0 | 19.052 | 28.431 | 45.769 | 71.377 | 90.705 | 104.233 | 119.366 | 169.416 | 281.338 |
Receivables | 297 | 2.542 | 3.916 | 1.964 | 6.257 | 2.974 | 9.398 | 29.990 | 39.763 | 63.250 |
Cash | 63 | 190 | 737 | 16.520 | 5.117 | 3.092 | 5.814 | 42.905 | 5.049 | 9.902 |
Shareholders Funds | -1.208 | -14.045 | -31.540 | -19.643 | 329 | 51.910 | 80.221 | 148.916 | 64.756 | 143.721 |
Social Capital | 45 | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 |
Debts | 1.568 | 36.660 | 64.655 | 83.895 | 82.461 | 50.433 | 43.024 | 45.430 | 177.771 | 231.289 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "4773 - 4773" | |||||||||
CAEN Financial Year |
4773
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Solius Pharm Srl